An interventional study of Microvessel Ultrasound Examination and Skin Biopsy in Non-Healing Ulcer of Skin, Non-healing Wound and Lower Extremity Wound, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Ulcer with a site in United States — 24 open to participants now, 27 under way, none of them phase 3. Ulcer · United States.
Among the 141 studies in Ulcer with a site in United States, this one is the 108th largest by planned enrollment of the 124 interventional ones that give a count, is one of 3 that started in 2023, is one of 60 with no phase, reaches primary completion later than 10 of the 26 other live ones, and was the 115th registered.
360 studies on the registry are indexed under Ulcer; 61 are open to participants now.
Browse Ulcer studies →24 of the 141 studies in Ulcer with a site in United States are open now. Recruiting first, the newest first:
UNCANCER LLC · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Athos Therapeutics Inc · Sites in United States
Ages 18–75
Sequence LifeScience, Inc. · Sites in United States
Ages 18+
BioLab Holdings · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Ulcer studies recruiting now, 30 (77%) set no upper age limit and 3 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 32 · Phase 3 18 · Phase 4 10
First in 1994; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 65 across 292 interventional studies indexed under Ulcer.
Median enrollment 95 across the 124 interventional studies, 87 across the 16 observational. Of the 97 that completed or were terminated, 43 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 141 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 1 study filed under Ulcer — fewer than ten, so there is no comparison to draw.
13 of the studies in Ulcer with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06674980C5 BiomedicalClinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs | 2026-11-22 |
| NCT05739149Mayo ClinicA Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers | 2026-12-10 |
| NCT07364630BioLab HoldingsEfficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers | 2027-01 |
| NCT06616844ConvaTec Inc.IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers | 2027-03 |
| NCT06742801Medtronic EndovascularOnyx™ Liquid Embolic IDE Clinical Study | 2027-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 141 studies in Ulcer with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to explore the use of high-resolution microvessel ultrasound imaging system to look for scarring and to monitor wound healing and to see if treatment affects the amount of tiny vessels and circulation around the wound.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with chronic diabetic ulcers and venous ulcers will undergo wound debridement and treatment as standard of care and receive research microvessel ultrasound examination and two skin biopsies
Diagnostic Test: Microvessel Ultrasound Examination · Procedure: Skin Biopsy
Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin
Dermatology will remove a small piece of skin from the affected ulcer area and control skin
Microvessel imaging
Number of subject's microvessel imaging results that correlate to the standard of care clinical assessment of wound healing
Time frame: 3 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.
Of 44 non-industry interventional studies with no phase under Ulcer, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 64. This study's planned 36 months is above that.
Counting every sponsor, half of 69 studies reached it within 25 months; a quarter within 10 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.